4[1]Mclaughlin T, Reaven G. Insulin resis-tance and hypertension[J]. Geriatrics,2000,55(6)∶28-32.
5[2]Shimamoto K. Insulin resistance synd-rome and hypertension[J]. Hokkaido Igaku Zasshi, 2000,75(1)∶9-14.
6Lo MW, Goldberg MR, Mccrea JB, et al. Pharmacokinetic of losartan, an angiotensin Ⅱ receptor antagonist and it active metabolite EXP3174 in human. Clin Pharmacol Ther 1995,58 (6) , 641-649.
7Yu G, Liang X, Xie X, et al. Apoptosis, myocardial fibrosis and angiotensin Ⅱ in the left ventricle of hypertensive rats treated with fosinopril or losartan. Chin Med J (Engl) 2002, 115 (9) : 1287-1291.
8Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium an angiotension Ⅱ receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensionconverting enzyme inhibiters for the treatment of systemic hypertension,Am J Cardiol 1995,75(12): 793-795.
9Weir MR, Elkins M, Liss C, et al. Efficacy, tolerability and guality of life of losartan, alone or with hydrochlorothiazide, versus nifedepine GITS in patient with essential hypertension. Clln Ther 1996,18 (3) , 411-428.
10Gradman AH, Brady WE, Gazdich LP, et al. A multicenter,randomized, double-blind placebo controlled, 8 week trial of the efficacy and tohrability of one-daily lOOmg losartan/hydrochlorothiazide 25mg and losartan 50mg/hydrochlorothiazide 12.5mg in the treatment of moderate-severe essential hypertension. Clin Ther 2002,24(7) : 1049-1061.
8KUMARRAJA M, PITCHUMANI K. Simple and efficient reduction of nitroarenes by hydrazine in faujasite zeolites. Applied Catalysis A : General, 2004,265 : 135- 139.
9YANG L C, QI C M, ZHANG G X, et al. Faerie Synthesis of Nonpeptide Angiotensin Receptor Antagonidts.J.Heteroeyclie Chem, ,2003,40: 1 107-1 112.
